Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three Cell And Gene Therapies Reach Critical Review Stage In EU

BMS, bluebird bio And PTC Therapeutics Need To Address Reviewers' Outstanding Issues

Executive Summary

A number of advanced therapies are likely to be approved in the EU this year.

You may also be interested in...



EU Crunch Time For Bluebird’s Neurodegenerative Disorder Gene Therapy

The EU could become the first market in which eli-cel is approved if the gene therapy for cerebral adrenoleukodystrophy this week passes muster with the European Medicines Agency.

EMA Says Yes To Eight New Medicines, Holds Fire On Others

The European Medicines Agency today announced the new medicines it believes should be approved for use across the EU.

Pivotal Moment In EU For Potential New Drugs

Decisions are due on several EU marketing applications at the March meeting of the European Medicines Agency’s drug evaluation committee, the CHMP. Also, a number of companies might be asked to address outstanding issues the CHMP has about products they want to market that are near the final stages of review.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel